Patents
The Future of Enablement for Antibody Genus Claims
Amgen v. Sanofi presents an important issue regarding the extent to which a patent claim encompassing a genus of antibodies can withstand a 35 U.S.C. § 112 enablement challenge.
ABA-IPL Annual Section Meeting | April 7–16, 2021
December 17, 2020 | Why the “Essence” of an Invention Is as Important as the Claims